Last Updated on October 30, 2025 by The Health Master
USFDA Inspection
Jubilant Pharmova Limited is pleased to announce that the U.S. Food and Drug Administration inspection (USFDA inspection) has been completed at its U.S. subsidiary, Jubilant Cadista Pharmaceuticals Inc., which has culminated in a successful outcome.
This particular check is known as a Post-marketing Adverse Drug Experience (PADE) inspection, which focuses on assessing the reporting and management of adverse events post-approval and marketing by the company.
In other words, it’s an assessment of how well they track their internal systems for safety reporting.
Zero Findings Means Success
The conclusion of the USFDA inspection resulted in zero observations from the USFDA.
This is an overall success for the company.
In layman’s terms, this means that nothing was wrong with processes, people, systems, or operations during the USFDA inspection.
There were no findings or recommendations.
This is the highest outcome one could hope for and reflects Jubilant’s effective commitment to international standards of quality, safety, and compliance.
There are no better outcomes for successful pharmaceutical operations than a USFDA determination like this.
Who is Jubilant Pharma?
Jubilant Pharma is a global pharmaceutical company with diversified offerings.
Jubilant is a subsidiary of Jubilant Pharmova Limited with its headquarters in Singapore. Some of their diverse services include:
- Radiopharmaceuticals:
- Allergy Immunotherapy:
- Contract Manufacturing:
Thus, the USFDA determination for clean inspections translates to operations across the board for the whole company, necessary for these diverse sectors of business.
Q: What does “zero observations” mean, and why is it important?
A: “Zero observations” means the USFDA did not identify any deficiencies within the company’s practices. This indicates that the company is in full compliance with stringent federal regulations and is an indicator of quality control and safety practice efforts. This is the best rating a company can receive.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
USFDA issued Form 483 to Lupin with 4 observations: Pune
USFDA issued Form 483 to Lupin with 6 observations: Nagpur
USFDA issued Form 483 to Reddy’s with 5 observations: Hyderabad
USFDA issued Form 483 to Biocon with 5 observations
USFDA issued Form 483 to Lupin with 4 observations: Pune
Drug alert: 94 drug samples declared as NSQ in August 2025
USFDA issued Form 483 to Lupin with 6 observations: Nagpur
Haryana: ₹5,000 Crore investment Plan for Pharma and Medical Device
CDSCO Redefines Cocrystals as ‘New Drugs’
NPPA fixed retail price of 9 formulations: September 2025
USFDA issued Form 483 to Reddy’s with 5 observations: Hyderabad
USFDA approval granted for blood clotting drug: Alembic
